Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

BiTE Antibodies Show Encouraging Activity in Myeloma, AML

December 11th 2018

Data from 2 early-stage trials of bispecific T-cell engager antibody constructs in relapsed/refractory hematologic malignancies demonstrated antitumor activity and early evidence of tolerability.

Nivolumab Combo Shows Early Activity in Relapsed/Refractory AML

December 10th 2018

The combination of nivolumab and azacitidine demonstrated favorable responses and overall survival in patients with relapsed/refractory acute myeloid leukemia.

Dr. Perl on CAR T Cells in Pediatric Leukemia

December 5th 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses the promise of CAR T cells in the treatment of pediatric leukemia.

Dr. Martin on MRD Status in Multiple Myeloma

December 4th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses minimal residual disease (MRD) status in multiple myeloma.

Mutation in BCL2 Protein Confers Resistance to Venetoclax

December 4th 2018

A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.

Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL

December 4th 2018

Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

Dr. Shah on Initial Results for bb21217 in Multiple Myeloma

December 4th 2018

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.

Quizartinib Update Presented as FDA Weighs AML Approval

December 4th 2018

The overall survival benefit with quizartinib in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia was observed across patient subgroups and reproduced consistently across sensitivity analyses.

Venetoclax With HMAs Shows Promise in AML for Patients Ineligible for High-Dose Chemo

December 3rd 2018

More than 70% of older patients ineligible for intensive chemotherapy for acute myeloid leukemia had complete responses to venetoclax combined with hypomethylating agents, preliminary results from clinical trials have shown.

New Prediction Model Improves Personalized Insight Into MDS Survival

December 3rd 2018

An approach using machine learning to analyze genomic and clinical data from patients with myelodysplastic syndromes could replace the gold standard of predicting how long patients may live with the disease.

Dr. Leonard on AUGMENT Trial Results in Non-Hodgkin Lymphoma

December 3rd 2018

John P. Leonard, MD, associate dean for clinical research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, discusses the key takeaway from the phase III AUGMENT trial, a randomized study of lenalidomide (Revlimid) plus rituximab (Rituxan) (R2) versus rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma, during the 2018 ASH Annual Meeting.

Dr. Gauthier on Findings for CD19-Targeted CAR T Cells Plus Ibrutinib in CLL

December 3rd 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses a study comparing efficacy and toxicity of CD19-specific chimeric antigen receptor (CAR) T cells alone or in combination with ibrutinib in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) during the 2018 ASH Annual Meeting.

Mosunetuzumab Shows Promise for Non-Hodgkin Lymphoma

December 3rd 2018

The CD3 and CD20 bispecific antibody mosunetuzumab demonstrated promising complete remission rates with tolerable toxicity for patients with relapsed/refractory B-cell indolent and aggressive non-Hodgkin lymphoma.

Anti-PD-1 Plus Umbralisib/Ublituximab Hits 90% Response in CLL

December 3rd 2018

The triplet regimen of pembrolizumab (Keytruda) plus umbralisib and ublituximab reached a 90% response rate in patients with relapsed/refractory chronic lymphocytic leukemia.

Beat AML Trial Proves Feasibility of Rapid Treatment Assignment Following Diagnosis

December 3rd 2018

Initial findings from the Beat AML study showed that rapid genetic testing in patients with AML was feasible and helpful, and that a precision medicine approach is possible for these patients, who must be treated urgently given the disease’s rapid progression.

Ibrutinib Efficacy Sustained at 7-Year Analysis for CLL

December 3rd 2018

Single-agent ibrutinib continued to demonstrate strong results after 7 years of follow-up in both the frontline and heavily pretreated, relapsed/refractory setting for patients with CLL and SLL.

Checkpoint Inhibition May Improve CAR T-Cell Persistence

December 2nd 2018

Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.

Daratumumab Safe and Effective When Added to VRd in Newly Diagnosed MM

December 2nd 2018

Daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients and a stringent complete response or CR in 63% of patients at the end of consolidation therapy in the run-in phase of an open-label study of transplant-eligible patients with newly diagnosed multiple myeloma.

Dr. Ravandi on BiTE Antibody AMG 330 Data in Relapsed/Refractory AML

December 2nd 2018

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase I first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE) antibody construct, in patients with relapsed/refractory acute myeloid leukemia (AML) during the 2018 ASH Annual Meeting.

Dr. Phillips on Activity With Acalabrutinib Plus Bendamustine/Rituximab in MCL

December 2nd 2018

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.